Belgium· BE-AMP-SAM396846-00
Rasilamlo 150 mg - 10 mg
A aliskiren and amlodipine product containing aliskiren hemifumarate, registered in Belgium by Novartis Europharm. The same ATC class is registered in 2 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Aliskiren and amlodipine is registered in 2 of 19 countries.
Countries holding a registration under ATC C09XA53 (aliskiren and amlodipine), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 2 of them publish a price we can compare per daily dose
Aliskiren and amlodipine · ATC C09XA53
2 / 19 countries
- Belgiumprice
- Finlandprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Aliskiren Hemifumarate
- Manufacturer
- Novartis Europharm
- Country
- Belgium (BE)
- ATC code
- C09XA53
- ATC class
- Aliskiren and amlodipine
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
54 interactions on record for aliskiren and amlodipine.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aliskiren and amlodipine · interactions on record
54 records
54 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Aliskiren and amlodipine in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/68312f43-87b9-4522-8cd7-da4dafc8a5cb GET /v1/drugs/68312f43-87b9-4522-8cd7-da4dafc8a5cb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "REVOKED",
"name_en": "Rasilamlo 150 mg - 10 mg",
"name_fr": "Rasilamlo 150 mg - 10 mg",
"name_nl": "Rasilamlo 150 mg - 10 mg",
"amp_code": "SAM396846-00",
"strengths": [
"150.0000",
"10.0000"
],
"pack_count": 14,
"substances": [
"Aliskiren Hemifumarate",
"Aliskiren",
"Amlodipine Besilate",
"Amlodipine"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Aliskiren and Amlodipine",
"authorisation_numbers": [
"EU/1/11/686/027",
"EU/1/11/686/028"
]
}See everything about aliskiren and amlodipine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.